Volastra
1 follower
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and p... Read more
Org chart
Charles Hugh-Jones
Chief Executive Officer
Charles Hugh-Jones
Collapse
Michael Su
Chief Scientific Officer
Rachel Zolot Schwartz
Chief Business Officer
Scott Drutman
Chief Medical Officer
Joseph Avallone
Controller
Sabine Bisson
VP, Development Leadership
Jianmin Mao
VP, CMC
Yazen Jmeian
Director, Bio-therapeutics
Jacqueline Gonzalez
Executive Assistant
Teams
View all
